Research
Hormonal
Insulin-lowering diets have not yet been conclusively demonstrated to improve cancer-specific endpoints such as tumor response, disease-specific survival, or overall survival in clinical settings.
Do not rely on insulin-lowering diets as a cure or primary treatment for metastatic cancer. While they improve metabolic health and are safe, they have not been proven to extend life or shrink tumors in humans. Use them only as an adjunct to standard care under medical supervision.
StrongRefutesHIGH confidence
Though promising, the anti-cancer efficacy of these interventions, such as impact on tumor response, disease-specific-, and overall survival, have not yet been conclusively demonstrated.
Why this rating
Based on the review of 9 clinical studies, none provided conclusive survival data.
Source
Insulin-Lowering Diets in Metastatic Cancer
Sherry Shen et al. · Nutrients · 2022
DOI 10.3390/nu14173542
narrative_reviewCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →